Medical Care

Global Peptide and Oligonucleotide CDMO Market Research Report 2025

The global market for Peptide and Oligonucleotide CDMO was valued at US$ 1918 million in the year 2024 and is projected to reach a revised size of US$ 3704 million by 2031, growing at a CAGR of 10.0% during the forecast period.
North American market for Peptide and Oligonucleotide CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Peptide and Oligonucleotide CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Peptide and Oligonucleotide CDMO in Pharmaceutical and Biotechnology Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Peptide and Oligonucleotide CDMO include Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, Polypeptide Group, Bachem Holding AG, Wuxi Apptec Co., Ltd., Ajinomoto Co., Inc., Rentschler Biopharma SE, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Peptide and Oligonucleotide CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide and Oligonucleotide CDMO.
The Peptide and Oligonucleotide CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide and Oligonucleotide CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide and Oligonucleotide CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza Group Ltd.
Thermo Fisher Scientific Inc.
Merck KGaA
Catalent, Inc.
Genscript Biotech Corporation
Polypeptide Group
Bachem Holding AG
Wuxi Apptec Co., Ltd.
Ajinomoto Co., Inc.
Rentschler Biopharma SE
Corden Pharma GmbH
Senn Chemicals AG
Almac Group
Lonza Custom Manufacturing
Creative Peptides
Swiss Customized Synthesis
Syngene
Eurogentec
Segment by Type
Peptide CDMO
Oligonucleotide CDMO
Segment by Application
Pharmaceutical and Biotechnology Companies
Research Institutes
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide and Oligonucleotide CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Peptide CDMO
1.2.3 Oligonucleotide CDMO
1.3 Market by Application
1.3.1 Global Peptide and Oligonucleotide CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research Institutes
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide and Oligonucleotide CDMO Market Perspective (2020-2031)
2.2 Global Peptide and Oligonucleotide CDMO Growth Trends by Region
2.2.1 Global Peptide and Oligonucleotide CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peptide and Oligonucleotide CDMO Historic Market Size by Region (2020-2025)
2.2.3 Peptide and Oligonucleotide CDMO Forecasted Market Size by Region (2026-2031)
2.3 Peptide and Oligonucleotide CDMO Market Dynamics
2.3.1 Peptide and Oligonucleotide CDMO Industry Trends
2.3.2 Peptide and Oligonucleotide CDMO Market Drivers
2.3.3 Peptide and Oligonucleotide CDMO Market Challenges
2.3.4 Peptide and Oligonucleotide CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide and Oligonucleotide CDMO Players by Revenue
3.1.1 Global Top Peptide and Oligonucleotide CDMO Players by Revenue (2020-2025)
3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Peptide and Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peptide and Oligonucleotide CDMO Revenue
3.4 Global Peptide and Oligonucleotide CDMO Market Concentration Ratio
3.4.1 Global Peptide and Oligonucleotide CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide and Oligonucleotide CDMO Revenue in 2024
3.5 Global Key Players of Peptide and Oligonucleotide CDMO Head office and Area Served
3.6 Global Key Players of Peptide and Oligonucleotide CDMO, Product and Application
3.7 Global Key Players of Peptide and Oligonucleotide CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide and Oligonucleotide CDMO Breakdown Data by Type
4.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Type (2020-2025)
4.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Type (2026-2031)
5 Peptide and Oligonucleotide CDMO Breakdown Data by Application
5.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Application (2020-2025)
5.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peptide and Oligonucleotide CDMO Market Size (2020-2031)
6.2 North America Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025)
6.4 North America Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide and Oligonucleotide CDMO Market Size (2020-2031)
7.2 Europe Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025)
7.4 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size (2020-2031)
8.2 Asia-Pacific Peptide and Oligonucleotide CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide and Oligonucleotide CDMO Market Size (2020-2031)
9.2 Latin America Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025)
9.4 Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size (2020-2031)
10.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza Group Ltd.
11.1.1 Lonza Group Ltd. Company Details
11.1.2 Lonza Group Ltd. Business Overview
11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Introduction
11.1.4 Lonza Group Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.1.5 Lonza Group Ltd. Recent Development
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Details
11.2.2 Thermo Fisher Scientific Inc. Business Overview
11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Introduction
11.2.4 Thermo Fisher Scientific Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.2.5 Thermo Fisher Scientific Inc. Recent Development
11.3 Merck KGaA
11.3.1 Merck KGaA Company Details
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Introduction
11.3.4 Merck KGaA Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.3.5 Merck KGaA Recent Development
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Details
11.4.2 Catalent, Inc. Business Overview
11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Introduction
11.4.4 Catalent, Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.4.5 Catalent, Inc. Recent Development
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Details
11.5.2 Genscript Biotech Corporation Business Overview
11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Introduction
11.5.4 Genscript Biotech Corporation Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.5.5 Genscript Biotech Corporation Recent Development
11.6 Polypeptide Group
11.6.1 Polypeptide Group Company Details
11.6.2 Polypeptide Group Business Overview
11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Introduction
11.6.4 Polypeptide Group Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.6.5 Polypeptide Group Recent Development
11.7 Bachem Holding AG
11.7.1 Bachem Holding AG Company Details
11.7.2 Bachem Holding AG Business Overview
11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Introduction
11.7.4 Bachem Holding AG Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.7.5 Bachem Holding AG Recent Development
11.8 Wuxi Apptec Co., Ltd.
11.8.1 Wuxi Apptec Co., Ltd. Company Details
11.8.2 Wuxi Apptec Co., Ltd. Business Overview
11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Introduction
11.8.4 Wuxi Apptec Co., Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.8.5 Wuxi Apptec Co., Ltd. Recent Development
11.9 Ajinomoto Co., Inc.
11.9.1 Ajinomoto Co., Inc. Company Details
11.9.2 Ajinomoto Co., Inc. Business Overview
11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Introduction
11.9.4 Ajinomoto Co., Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.9.5 Ajinomoto Co., Inc. Recent Development
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Details
11.10.2 Rentschler Biopharma SE Business Overview
11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Introduction
11.10.4 Rentschler Biopharma SE Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.10.5 Rentschler Biopharma SE Recent Development
11.11 Corden Pharma GmbH
11.11.1 Corden Pharma GmbH Company Details
11.11.2 Corden Pharma GmbH Business Overview
11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Introduction
11.11.4 Corden Pharma GmbH Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.11.5 Corden Pharma GmbH Recent Development
11.12 Senn Chemicals AG
11.12.1 Senn Chemicals AG Company Details
11.12.2 Senn Chemicals AG Business Overview
11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Introduction
11.12.4 Senn Chemicals AG Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.12.5 Senn Chemicals AG Recent Development
11.13 Almac Group
11.13.1 Almac Group Company Details
11.13.2 Almac Group Business Overview
11.13.3 Almac Group Peptide and Oligonucleotide CDMO Introduction
11.13.4 Almac Group Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.13.5 Almac Group Recent Development
11.14 Lonza Custom Manufacturing
11.14.1 Lonza Custom Manufacturing Company Details
11.14.2 Lonza Custom Manufacturing Business Overview
11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Introduction
11.14.4 Lonza Custom Manufacturing Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.14.5 Lonza Custom Manufacturing Recent Development
11.15 Creative Peptides
11.15.1 Creative Peptides Company Details
11.15.2 Creative Peptides Business Overview
11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Introduction
11.15.4 Creative Peptides Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.15.5 Creative Peptides Recent Development
11.16 Swiss Customized Synthesis
11.16.1 Swiss Customized Synthesis Company Details
11.16.2 Swiss Customized Synthesis Business Overview
11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Introduction
11.16.4 Swiss Customized Synthesis Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.16.5 Swiss Customized Synthesis Recent Development
11.17 Syngene
11.17.1 Syngene Company Details
11.17.2 Syngene Business Overview
11.17.3 Syngene Peptide and Oligonucleotide CDMO Introduction
11.17.4 Syngene Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.17.5 Syngene Recent Development
11.18 Eurogentec
11.18.1 Eurogentec Company Details
11.18.2 Eurogentec Business Overview
11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Introduction
11.18.4 Eurogentec Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025)
11.18.5 Eurogentec Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Peptide CDMO
Table 3. Key Players of Oligonucleotide CDMO
Table 4. Global Peptide and Oligonucleotide CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Peptide and Oligonucleotide CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Peptide and Oligonucleotide CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Peptide and Oligonucleotide CDMO Market Share by Region (2020-2025)
Table 8. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Peptide and Oligonucleotide CDMO Market Share by Region (2026-2031)
Table 10. Peptide and Oligonucleotide CDMO Market Trends
Table 11. Peptide and Oligonucleotide CDMO Market Drivers
Table 12. Peptide and Oligonucleotide CDMO Market Challenges
Table 13. Peptide and Oligonucleotide CDMO Market Restraints
Table 14. Global Peptide and Oligonucleotide CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Peptide and Oligonucleotide CDMO Market Share by Players (2020-2025)
Table 16. Global Top Peptide and Oligonucleotide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2024)
Table 17. Ranking of Global Top Peptide and Oligonucleotide CDMO Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Peptide and Oligonucleotide CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Peptide and Oligonucleotide CDMO, Headquarters and Area Served
Table 20. Global Key Players of Peptide and Oligonucleotide CDMO, Product and Application
Table 21. Global Key Players of Peptide and Oligonucleotide CDMO, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Peptide and Oligonucleotide CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2020-2025)
Table 25. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2026-2031)
Table 27. Global Peptide and Oligonucleotide CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2020-2025)
Table 29. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2026-2031)
Table 31. North America Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 46. Lonza Group Ltd. Company Details
Table 47. Lonza Group Ltd. Business Overview
Table 48. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product
Table 49. Lonza Group Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 50. Lonza Group Ltd. Recent Development
Table 51. Thermo Fisher Scientific Inc. Company Details
Table 52. Thermo Fisher Scientific Inc. Business Overview
Table 53. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product
Table 54. Thermo Fisher Scientific Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 55. Thermo Fisher Scientific Inc. Recent Development
Table 56. Merck KGaA Company Details
Table 57. Merck KGaA Business Overview
Table 58. Merck KGaA Peptide and Oligonucleotide CDMO Product
Table 59. Merck KGaA Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 60. Merck KGaA Recent Development
Table 61. Catalent, Inc. Company Details
Table 62. Catalent, Inc. Business Overview
Table 63. Catalent, Inc. Peptide and Oligonucleotide CDMO Product
Table 64. Catalent, Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 65. Catalent, Inc. Recent Development
Table 66. Genscript Biotech Corporation Company Details
Table 67. Genscript Biotech Corporation Business Overview
Table 68. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product
Table 69. Genscript Biotech Corporation Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 70. Genscript Biotech Corporation Recent Development
Table 71. Polypeptide Group Company Details
Table 72. Polypeptide Group Business Overview
Table 73. Polypeptide Group Peptide and Oligonucleotide CDMO Product
Table 74. Polypeptide Group Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 75. Polypeptide Group Recent Development
Table 76. Bachem Holding AG Company Details
Table 77. Bachem Holding AG Business Overview
Table 78. Bachem Holding AG Peptide and Oligonucleotide CDMO Product
Table 79. Bachem Holding AG Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 80. Bachem Holding AG Recent Development
Table 81. Wuxi Apptec Co., Ltd. Company Details
Table 82. Wuxi Apptec Co., Ltd. Business Overview
Table 83. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product
Table 84. Wuxi Apptec Co., Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 85. Wuxi Apptec Co., Ltd. Recent Development
Table 86. Ajinomoto Co., Inc. Company Details
Table 87. Ajinomoto Co., Inc. Business Overview
Table 88. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product
Table 89. Ajinomoto Co., Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 90. Ajinomoto Co., Inc. Recent Development
Table 91. Rentschler Biopharma SE Company Details
Table 92. Rentschler Biopharma SE Business Overview
Table 93. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product
Table 94. Rentschler Biopharma SE Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 95. Rentschler Biopharma SE Recent Development
Table 96. Corden Pharma GmbH Company Details
Table 97. Corden Pharma GmbH Business Overview
Table 98. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product
Table 99. Corden Pharma GmbH Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 100. Corden Pharma GmbH Recent Development
Table 101. Senn Chemicals AG Company Details
Table 102. Senn Chemicals AG Business Overview
Table 103. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product
Table 104. Senn Chemicals AG Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 105. Senn Chemicals AG Recent Development
Table 106. Almac Group Company Details
Table 107. Almac Group Business Overview
Table 108. Almac Group Peptide and Oligonucleotide CDMO Product
Table 109. Almac Group Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 110. Almac Group Recent Development
Table 111. Lonza Custom Manufacturing Company Details
Table 112. Lonza Custom Manufacturing Business Overview
Table 113. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product
Table 114. Lonza Custom Manufacturing Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 115. Lonza Custom Manufacturing Recent Development
Table 116. Creative Peptides Company Details
Table 117. Creative Peptides Business Overview
Table 118. Creative Peptides Peptide and Oligonucleotide CDMO Product
Table 119. Creative Peptides Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 120. Creative Peptides Recent Development
Table 121. Swiss Customized Synthesis Company Details
Table 122. Swiss Customized Synthesis Business Overview
Table 123. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product
Table 124. Swiss Customized Synthesis Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 125. Swiss Customized Synthesis Recent Development
Table 126. Syngene Company Details
Table 127. Syngene Business Overview
Table 128. Syngene Peptide and Oligonucleotide CDMO Product
Table 129. Syngene Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 130. Syngene Recent Development
Table 131. Eurogentec Company Details
Table 132. Eurogentec Business Overview
Table 133. Eurogentec Peptide and Oligonucleotide CDMO Product
Table 134. Eurogentec Revenue in Peptide and Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 135. Eurogentec Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
Table 139. Authors List of This Report


List of Figures
Figure 1. Peptide and Oligonucleotide CDMO Picture
Figure 2. Global Peptide and Oligonucleotide CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Peptide and Oligonucleotide CDMO Market Share by Type: 2024 VS 2031
Figure 4. Peptide CDMO Features
Figure 5. Oligonucleotide CDMO Features
Figure 6. Global Peptide and Oligonucleotide CDMO Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Peptide and Oligonucleotide CDMO Market Share by Application: 2024 VS 2031
Figure 8. Pharmaceutical and Biotechnology Companies Case Studies
Figure 9. Research Institutes Case Studies
Figure 10. Others Case Studies
Figure 11. Peptide and Oligonucleotide CDMO Report Years Considered
Figure 12. Global Peptide and Oligonucleotide CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Peptide and Oligonucleotide CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Peptide and Oligonucleotide CDMO Market Share by Region: 2024 VS 2031
Figure 15. Global Peptide and Oligonucleotide CDMO Market Share by Players in 2024
Figure 16. Global Top Peptide and Oligonucleotide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Peptide and Oligonucleotide CDMO Revenue in 2024
Figure 18. North America Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Peptide and Oligonucleotide CDMO Market Share by Country (2020-2031)
Figure 20. United States Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Peptide and Oligonucleotide CDMO Market Share by Country (2020-2031)
Figure 24. Germany Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Peptide and Oligonucleotide CDMO Market Share by Region (2020-2031)
Figure 32. China Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Peptide and Oligonucleotide CDMO Market Share by Country (2020-2031)
Figure 40. Mexico Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Peptide and Oligonucleotide CDMO Market Share by Country (2020-2031)
Figure 44. Turkey Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Peptide and Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Lonza Group Ltd. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 48. Thermo Fisher Scientific Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 49. Merck KGaA Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 50. Catalent, Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 51. Genscript Biotech Corporation Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 52. Polypeptide Group Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 53. Bachem Holding AG Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 54. Wuxi Apptec Co., Ltd. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 55. Ajinomoto Co., Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 56. Rentschler Biopharma SE Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 57. Corden Pharma GmbH Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 58. Senn Chemicals AG Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 59. Almac Group Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 60. Lonza Custom Manufacturing Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 61. Creative Peptides Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 62. Swiss Customized Synthesis Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 63. Syngene Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 64. Eurogentec Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2020-2025)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies